OncoLens

We're excited to see you at next week. Stop by our booth to discuss strategies to reimagine the delivery of cancer care, including coordinating care across wide provider networks or identifying appropriate clinical trials and biomarker tests, through AI, for your patients.

See you in Austin!

Association of Community Cancer Centers

In this recent study conducted by OncoLens to baseline and improve alignment of biomarker testing to guidelines, top barriers to biomarker testing were: 1) limited quantity of tissue available - 63% of respondents 2) reimbursement concerns including “potential cost to patient,” - 53% of respondents and 3) cumbersome process due to delays and long turnaround times for authorization, ordering, and/or delivery of results - 44% of respondents.
Liquid biopsy which can overcome some of these barriers was a low 4% of testing conducted and required more provider education/engagement. What barriers to do you see to faster market uptake of liquid biopsy?
https://meetings.asco.org/abstracts-presentations/224120

Program Guide – ASCO Meeting Program Guide Background: Limited data exists on next-generation sequencing (NGS) testing rates, utilization of single gene tests for therapy matching, use of liquid biopsies in therapy selection, or physician-perceived barriers to testing in hospital-based cancer centers. Initial project goal is to establish a b...